Brief: Lantern Pharma Reports Additional Positive Lp-184 Phase 1A Results Showing Durable Disease Control In Heavily Pre-Treated Advanced Cancer Patients
03/12/2025 13:41
Dec 3 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA : REPORTS ADDITIONAL POSITIVE LP-184 PHASE 1A RESULTS SHOWING DURABLE DISEASE CONTROL IN HEAVILY PRE-TREATED ADVANCED CANCER PATIENTS LANTERN PHARMA INC: CLINICAL TRIAL MET ALL PRIMARY ENDPOINTS FOR SAFETY, TOLERABILITY, AND ESTABLISHED A CLEAR RECOMMENDED PHASE 2 DOSE Source text: ID:nBw50QGYwa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Receives Taiwan Approvals To Open Next Stage Of Phase 2 Harmonic Trial Of Lp-300 In Never-Smoker, Egfr-Mutant Nsclc
Brief: Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update
Lantern Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
Lantern Pharma Inc expected to post a loss of 38 cents a share - Earnings Preview